Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Insider Placid Jover Sells 6,053 Shares

Key Points

• Teva Pharmaceutical Industries insider Placid Jover sold 6,053 shares for a total of $91,763.48, reducing their ownership by 47.19%.
• The company's stock price experienced a slight increase and was trading at $15.72, with a market cap of $18.03 billion.
• Teva reported an EPS of $0.66 for its last quarter, exceeding analysts' estimates, though revenue fell short at $4.18 billion.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) insider Placid Jover sold 6,053 shares of the stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $91,763.48. Following the transaction, the insider directly owned 6,774 shares of the company's stock, valued at $102,693.84. The trade was a 47.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Teva Pharmaceutical Industries Price Performance

TEVA stock traded up $0.24 during midday trading on Thursday, hitting $16.25. The company's stock had a trading volume of 7,662,831 shares, compared to its average volume of 12,237,846. The company has a 50 day moving average of $16.75 and a two-hundred day moving average of $16.51. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45. Teva Pharmaceutical Industries Ltd. has a 12 month low of $12.47 and a 12 month high of $22.80. The firm has a market capitalization of $18.64 billion, a price-to-earnings ratio of -101.59, a price-to-earnings-growth ratio of 0.93 and a beta of 0.62.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.02. The firm had revenue of $4.18 billion during the quarter, compared to analyst estimates of $4.34 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The business's quarterly revenue was up .3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.61 EPS. On average, analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

A number of hedge funds have recently bought and sold shares of the business. Orion Portfolio Solutions LLC increased its stake in Teva Pharmaceutical Industries by 11.9% in the 4th quarter. Orion Portfolio Solutions LLC now owns 12,302 shares of the company's stock worth $271,000 after purchasing an additional 1,310 shares in the last quarter. Wellington Management Group LLP lifted its stake in Teva Pharmaceutical Industries by 2.1% in the fourth quarter. Wellington Management Group LLP now owns 185,912 shares of the company's stock valued at $4,098,000 after buying an additional 3,816 shares during the period. Geode Capital Management LLC lifted its stake in Teva Pharmaceutical Industries by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 9,281,052 shares of the company's stock valued at $203,642,000 after buying an additional 489,041 shares in the last quarter. Trexquant Investment LP acquired a new stake in Teva Pharmaceutical Industries in the 4th quarter valued at $2,092,000. Finally, Huntington National Bank raised its holdings in shares of Teva Pharmaceutical Industries by 65.0% in the 4th quarter. Huntington National Bank now owns 5,880 shares of the company's stock valued at $130,000 after purchasing an additional 2,317 shares during the period. Institutional investors and hedge funds own 54.05% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a report on Monday, April 28th. Bank of America lifted their target price on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and raised their target price for the company from $21.00 to $23.00 in a report on Monday, May 12th. Finally, Truist Financial initiated coverage on shares of Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price target on the stock. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $24.71.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.